The ILUMIEN IV Trial
The ILUMIEN IV Trial sciprian@crf.org Wed, 10/02/2024 - 12:09 Publish Date --> 2 hours 5 minutes ago Teaser --> Ziad Ali and C. Michael Gibson ta
FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?
FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? sciprian@crf.org Wed, 10/02/2024 - 09:50 Michael O'Riordan In one study, outcomes were similar regardless of
TCTMD’s Top 10 Most Popular Stories for September 2024
TCTMD’s Top 10 Most Popular Stories for September 2024 sciprian@crf.org Tue, 10/01/2024 - 16:45 Shelley Wood Most of our top stories this month stemmed from the ESC Congress—
HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF
HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF sciprian@crf.org Tue, 10/01/2024 - 16:37 L.A. McKeown Among the trends in the report are a growing proportion of
Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity
Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity sciprian@crf.org Tue, 10/01/2024 - 15:53 Todd Neale Indications that the GLP-1 drug has greater benefits
Varipulse Pulsed-Field Ablation System Safe, Effective in Pivotal Trial
Varipulse Pulsed-Field Ablation System Safe, Effective in Pivotal Trial hdellabella@crf.org Mon, 09/30/2024 - 15:56 Todd Neale The system achieved safety and efficacy goals,